Treatment strategies for skeletal complications of cancer

James R. Berenson, Lakshmi Rajdev, Michael Broder

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Skeletal complications are a common result of many cancers, particularly of multiple myeloma and bone metastases of solid tumors originating in the breast, prostate or lung. A number of treatment options are available, including radiotherapy, radiopharmaceuticals, surgery and chemotherapy. Recently, bisphosphonates have emerged as a promising new treatment option for bone complications of cancer. These agents are potent inhibitors of osteoclast activity that bind to the bone matrix, are released during bone resorption, and are subsequently internalized by osteoclasts, where they interfere with biochemical pathways and induce osteoclast apoptosis. Bisphosphonates also antagonize osteoclastogenesis and promote the differentiation of osteoblasts. As a result, bisphosphonates inhibit tumor-induced osteolysis and reduce skeletal morbidity. Bisphosphonates are generally well tolerated, although they have recently been associated with osteonecrosis of the jaw, a painful and debilitating side effect that is only beginning to be understood. Despite this concern, bisphosphonates are an important tool in the management of skeletal complications of cancer, providing benefits for the treatment of hypercalcemia, osteolytic lesions and fractures, as well as offering amelioration of pain and improvement in quality of life.

Original languageEnglish (US)
Pages (from-to)1074-1077
Number of pages4
JournalCancer Biology and Therapy
Volume5
Issue number9
StatePublished - Sep 2006

Fingerprint

Diphosphonates
Osteoclasts
Neoplasms
Therapeutics
Bone Neoplasms
Osteolysis
Bone Matrix
Osteonecrosis
Radiopharmaceuticals
Hypercalcemia
Bone Resorption
Jaw
Osteoblasts
Multiple Myeloma
Osteogenesis
Prostate
Breast
Radiotherapy
Quality of Life
Apoptosis

Keywords

  • Bisphosphonates
  • Bone
  • Metastasis
  • Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Treatment strategies for skeletal complications of cancer. / Berenson, James R.; Rajdev, Lakshmi; Broder, Michael.

In: Cancer Biology and Therapy, Vol. 5, No. 9, 09.2006, p. 1074-1077.

Research output: Contribution to journalArticle

Berenson, JR, Rajdev, L & Broder, M 2006, 'Treatment strategies for skeletal complications of cancer', Cancer Biology and Therapy, vol. 5, no. 9, pp. 1074-1077.
Berenson, James R. ; Rajdev, Lakshmi ; Broder, Michael. / Treatment strategies for skeletal complications of cancer. In: Cancer Biology and Therapy. 2006 ; Vol. 5, No. 9. pp. 1074-1077.
@article{52a22b77462442ea85e0a4f04f907d47,
title = "Treatment strategies for skeletal complications of cancer",
abstract = "Skeletal complications are a common result of many cancers, particularly of multiple myeloma and bone metastases of solid tumors originating in the breast, prostate or lung. A number of treatment options are available, including radiotherapy, radiopharmaceuticals, surgery and chemotherapy. Recently, bisphosphonates have emerged as a promising new treatment option for bone complications of cancer. These agents are potent inhibitors of osteoclast activity that bind to the bone matrix, are released during bone resorption, and are subsequently internalized by osteoclasts, where they interfere with biochemical pathways and induce osteoclast apoptosis. Bisphosphonates also antagonize osteoclastogenesis and promote the differentiation of osteoblasts. As a result, bisphosphonates inhibit tumor-induced osteolysis and reduce skeletal morbidity. Bisphosphonates are generally well tolerated, although they have recently been associated with osteonecrosis of the jaw, a painful and debilitating side effect that is only beginning to be understood. Despite this concern, bisphosphonates are an important tool in the management of skeletal complications of cancer, providing benefits for the treatment of hypercalcemia, osteolytic lesions and fractures, as well as offering amelioration of pain and improvement in quality of life.",
keywords = "Bisphosphonates, Bone, Metastasis, Therapeutics",
author = "Berenson, {James R.} and Lakshmi Rajdev and Michael Broder",
year = "2006",
month = "9",
language = "English (US)",
volume = "5",
pages = "1074--1077",
journal = "Cancer Biology and Therapy",
issn = "1538-4047",
publisher = "Landes Bioscience",
number = "9",

}

TY - JOUR

T1 - Treatment strategies for skeletal complications of cancer

AU - Berenson, James R.

AU - Rajdev, Lakshmi

AU - Broder, Michael

PY - 2006/9

Y1 - 2006/9

N2 - Skeletal complications are a common result of many cancers, particularly of multiple myeloma and bone metastases of solid tumors originating in the breast, prostate or lung. A number of treatment options are available, including radiotherapy, radiopharmaceuticals, surgery and chemotherapy. Recently, bisphosphonates have emerged as a promising new treatment option for bone complications of cancer. These agents are potent inhibitors of osteoclast activity that bind to the bone matrix, are released during bone resorption, and are subsequently internalized by osteoclasts, where they interfere with biochemical pathways and induce osteoclast apoptosis. Bisphosphonates also antagonize osteoclastogenesis and promote the differentiation of osteoblasts. As a result, bisphosphonates inhibit tumor-induced osteolysis and reduce skeletal morbidity. Bisphosphonates are generally well tolerated, although they have recently been associated with osteonecrosis of the jaw, a painful and debilitating side effect that is only beginning to be understood. Despite this concern, bisphosphonates are an important tool in the management of skeletal complications of cancer, providing benefits for the treatment of hypercalcemia, osteolytic lesions and fractures, as well as offering amelioration of pain and improvement in quality of life.

AB - Skeletal complications are a common result of many cancers, particularly of multiple myeloma and bone metastases of solid tumors originating in the breast, prostate or lung. A number of treatment options are available, including radiotherapy, radiopharmaceuticals, surgery and chemotherapy. Recently, bisphosphonates have emerged as a promising new treatment option for bone complications of cancer. These agents are potent inhibitors of osteoclast activity that bind to the bone matrix, are released during bone resorption, and are subsequently internalized by osteoclasts, where they interfere with biochemical pathways and induce osteoclast apoptosis. Bisphosphonates also antagonize osteoclastogenesis and promote the differentiation of osteoblasts. As a result, bisphosphonates inhibit tumor-induced osteolysis and reduce skeletal morbidity. Bisphosphonates are generally well tolerated, although they have recently been associated with osteonecrosis of the jaw, a painful and debilitating side effect that is only beginning to be understood. Despite this concern, bisphosphonates are an important tool in the management of skeletal complications of cancer, providing benefits for the treatment of hypercalcemia, osteolytic lesions and fractures, as well as offering amelioration of pain and improvement in quality of life.

KW - Bisphosphonates

KW - Bone

KW - Metastasis

KW - Therapeutics

UR - http://www.scopus.com/inward/record.url?scp=33751111432&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751111432&partnerID=8YFLogxK

M3 - Article

C2 - 16969118

AN - SCOPUS:33751111432

VL - 5

SP - 1074

EP - 1077

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

SN - 1538-4047

IS - 9

ER -